SOURCE: Cytovance Biologics

Cytovance Biologics

April 14, 2015 04:00 ET

Cytovance® Biologics Inc., Creates Depth in Scientific Team With New Hires

OKLAHOMA CITY, OK--(Marketwired - April 14, 2015) - Cytovance® Biologics, Inc. of Oklahoma City, OK is pleased to announce the appointments of Dr. Keith Kropp Ph.D. and Anthony Hawrylechko, M.S. to the R&D Services group. Dr. Kropp is the Director of Mammalian Bioprocess and Protein Expression Technologies. In this new role, Dr. Kropp will oversee mammalian upstream process development and tech transfer activities while driving department goals around business and technology improvements. In addition, Dr. Kropp's expertise in protein expression, molecular biology, bioinformatics and high throughput screening technologies will allow him to advance further Cytovance's new capabilities in cell line development and microbial strain development using the Keystone Expression System™. Dr. Kropp has over 27 years' experience in biologics development and manufacture with broad training in protein expression technologies, upstream and downstream process development, tech transfer and CMC. He has served the industry in technical and management roles while working for Aventis Pharmaceuticals, Hoechst Marion Roussel, The Dow Chemical Company, Aptakon, Inc., Syntonix Pharmaceuticals and Xcellerex. Dr. Kropp received his Ph.D. in Biochemistry from the University of Missouri-Columbia and has authored over 15 peer-reviewed journal articles.

Anthony Hawrylechko, M.S. will serve as Director of Microbial Bioprocess. In this new role, Mr. Hawrylechko will oversee process development and tech transfer activities for Cytovance's rapidly growing microbial customer base. He will also help to realize plans for expansion of the fermentation laboratory including pilot plant and process characterization operations. With over 20 years of process development, design-of-experiments, characterization and GMP manufacturing experience, Anthony will provide technical and quality oversight to the microbial services area. Anthony earned a Masters Degree in Biochemistry from Queen's University in Kingston, Canada and has authored articles in biomanufacturing, Design-of-Experiments and QbD.

"We are very excited about this new growth in our company to further provide depth and the show of commitment in quality at Cytovance. Furthermore this is an exciting time to be a part of a growing company moving towards commercialization," said CEO Darren Head. Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cell line development, cGMP cell banking and storage, and support services from its Oklahoma City facilities.

Contact Information

  • Contact:
    Cheryl Tuck
    Marketing & Communications Manager